AIMEDIC 논문

In silico models for evaluating proarrhythmic risk of drugs

분류

Pub

일자

2020-06-01

출처

APL bioengineering

Safety evaluation of drugs requires examination of the risk of generating Torsade de Pointes (TdP) because it can lead to sudden cardiac death. Until recently, the QT interval in the electrocardiogram (ECG) has been used in the evaluation of TdP risk because the QT interval is known to be associated with the development of TdP. Although TdP risk evaluation based on QT interval has been successful in removing drugs with TdP risk from the market, some safe drugs may have also been affected due to the low specificity of QT interval-based evaluation. For more accurate evaluation of drug safety, the comprehensive in vitro proarrhythmia assay (CiPA) has been proposed by regulatory agencies, industry, and academia. Although the CiPA initiative includes in silico evaluation of cellular action potential as a component, attempts to utilize in silico simulation in drug safety evaluation are expanding, even to simulating …

콘텐츠 업데이트: API 게시 일자를 우선 사용합니다. 연구 초록과 원문 링크, 제품 페이지의 사용 목적 및 제한사항을 함께 확인하세요.